These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8253340)

  • 1. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
    Younes M; Lebovitz RM; Lechago LV; Lechago J
    Gastroenterology; 1993 Dec; 105(6):1637-42. PubMed ID: 8253340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
    Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
    Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma.
    Rice TW; Goldblum JR; Falk GW; Tubbs RR; Kirby TJ; Casey G
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1132-7. PubMed ID: 7983883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time gated fluorescence spectroscopy in Barrett's oesophagus.
    Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
    Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.
    Kim R; Clarke MR; Melhem MF; Young MA; Vanbibber MM; Safatle-Ribeiro AV; Ribeiro U; Reynolds JC
    Dig Dis Sci; 1997 Dec; 42(12):2453-62. PubMed ID: 9440619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus.
    Rioux-Leclercq N; Turlin B; Sutherland F; Heresbach N; Launois B; Campion JP; Ramee MP
    Oncol Rep; 1999; 6(4):877-82. PubMed ID: 10373674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
    Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
    Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
    Trakál E; Guidi A; Butti AL; Trakál JJ; Sambuelli R; Zárate FE
    Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.
    Eisen GM; Montgomery EA; Azumi N; Hartmann DP; Bhargava P; Lippman M; Benjamin SB
    Gastrointest Endosc; 1999 Dec; 50(6):814-8. PubMed ID: 10570342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.
    Helminen O; Melkko J; Saarnio J; Sihvo E; Kuopio T; Ohtonen P; Kauppila JH; Karttunen TJ; Huhta H
    Virchows Arch; 2022 Sep; 481(3):467-476. PubMed ID: 35614270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
    Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
    Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
    J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
    World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus.
    Giménez A; Minguela A; Parrilla P; Bermejo J; Pérez D; Molina J; García AM; Ortiz MA; Alvarez R; de Haro LM
    Cancer; 1998 Aug; 83(4):641-51. PubMed ID: 9708926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.